BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity

Hairy cell leukemia (HCL) shows unique clinicopathological and biological features. HCL responds well to purine analogs but relapses are frequent and novel therapies are required. BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-cell lymphomas, including HCL-like leukem...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood
Autores principales: Pettirossi, Valentina, Santi, Alessia, Imperi, Elisa, Russo, Guido, Pucciarini, Alessandra, Bigerna, Barbara, Schiavoni, Gianluca, Fortini, Elisabetta, Spanhol-Rosseto, Ariele, Sportoletti, Paolo, Mannucci, Roberta, Martelli, Maria Paola, Klein-Hitpass, Ludger, Falini, Brunangelo, Tiacci, Enrico
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2015
Materias:
Plenary Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4366655/
https://ncbi.nlm.nih.gov/pubmed/25480661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-10-603100
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares